



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)

Tel. : (0731) 2517677 | **E-mail :** beryl drugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

Date: 11.08.2021

To,

The Secretary,
Department of Corporate Services,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400001

Scrip Code: 524606

Sub.: Disclosure of Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sirs,

Pursuant to Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its 35th Board Meeting held on 11.08.2021 has approved the Unaudited Financial Results of the Company for the Quarter ended 30.06.2021.

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited


Sudhir Sethi
Chairman & Director
DIN: 00090172



ANNEXURE I

Submission of Unaudited/ Audited Financial Result by Companies Other than Banks

Part I

Statement of standalone Unaudited Result for the Quarter/year ended 30/06/2021

(Rs In 000)

Particulars	Quarter ended		Year ended	
	3 months ended (30.06.2021)	Preceding 3 months ended (31.03.2021)	Corresponding 3 months ended in the previous year (30-06-2020)	Previous year ended (31-03-2021)
	Unaudited	Audited	Unaudited	Audited
(Refer Notes Below)				
1 Revenue From Operations				
Net sales or Revenue from Operations	46098.000	60647.000	26965.000	140929.000
Other operating revenues	385.000	-3902.000	51.000	1871.000
Total Revenue from operations (net)	46483.000	56745.000	27016.000	142800.000
2 Expenses				
(a) Cost of materials consumed	24601.000	24691.000	16399.000	74517.000
(b) Purchases of stock-in-trade	0.000	0.000	0.000	0.000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-423.000	10750.000	-2437.000	-327.000
(d) Employee benefit expense	3049.000	3278.000	2514.000	11768.000
(e) Finance costs	1116.000	1412.000	1381.000	4657.000
(f) Depreciation and amortisation expense	2987.000	2359.000	3459.000	12735.000
(g) Other Expenses	12168.000	15617.000	7441.000	40489.000
Total expenses	43498.000	58107.000	28757.000	143839.000
3 Profit (loss) from operations before exceptional and extraordinary items and tax	2985.000	-1362.000	-1741.000	-1039.000
4 Exceptional Items	0.000	4518.000	0.000	4518.000
5 profit (loss) before extraordinary items and tax	2985.000	3156.000	-1741.000	3479.000
6 Extraordinary Items	0.000	0.000	0.000	0.000
7 Profit (loss) before tax	2985.000	3156.000	-1741.000	3479.000
8 Tax Expense				
Current tax	0.000	-460.000	0.000	8.000
Deferred tax	-410.000	2444.000	219.000	1075.000
Total Tax Expenses	-410.000	1984.000	219.000	1083.000
9 Net Profit (loss) for the period from continuing operations	3395.000	1172.000	-1960.000	2396.000
10 Net Profit (loss) from discontinuing operations before tax	0.000	0.000	0.000	0.000
11 Tax Expense of discontinuing operations	0.000	0.000	0.000	0.000
12 Net Profit (loss) from discontinuing operations after tax	0.000	0.000	0.000	0.000
13 Net Profit (loss) for the Period	3395.000	1172.000	-1960.000	2396.000
14 Other comprehensive income	-372.000	570.000	-634.000	643.000
15 Total Comprehensive Income	3023.000	1742.000	-2594.000	3039.000
16 Details of equity share capital				
Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000
Face value of equity share capital	10.000	10.000	10.000	10.000
17 Earnings per share				
i Basic earnings per share before extraordinary items	0.67	0.23	-0.39	0.47
ii Diluted earnings per share before extraordinary items	0.67	0.23	-0.39	0.47

Notes :

- The above financial results have been prepared in accordance with the recognition and measurement principles stated therein prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Agreement Regulation.
- The above results for the quarter ended 30th June 2021 which have been subjected to Limited Review by Statutory Auditors of the Company were reviewed and recommended by the Audit Committee and subsequently by the Board of Directors at its meeting held on 11th August, 2021 in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015.
- The Income from Operations is from one segment namely "Pharmaceutical Industry" as per Ind AS 108 "Operating Segments".
- The figures for the quarter ended March 31, 2021 are balancing figures between audited figures in respect of full financial year ended March 31, 2021 and the unaudited published figure up to December 31, 2020 being the end of third quarter of the financial year which were subjected to limited review.
- The Company is not much affected due to lockdown due to COVID-19. The Company is dealing in manufacturing of Drugs and medicines which falls in essential commodities hence duly permitted by local administration to work even during lockdown. But the management does not foresee any material impact on its business due to COVID-19.
- The figures for the previous periods have been regrouped/ reclassified wherever necessary to confirm to current period classification.
- Depreciation is provided on Written down value method on the estimated remaining useful lives of the assets.
- Revenue from Operations is net of GST.
- Earnings per Share amount is Shown in Rupees.

Place : Indore
 Date : 11.08.2021


 For and behalf of the Board

 Sanjay Sethi
 Managing Director

PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-2520955

E-MAIL: caprateekjain@gmail.com



Independent Auditor's Review Report on the Quarterly unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with SEBI Circular No. CIRJCFD/CMDI/44/2019 dated March 29, 2019

To,
The Board of Directors
Beryl Drugs Limited
133, Kanchan Bagh,
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **BERYL DRUGS LIMITED** ("the Company") for the quarter ended **30th June, 2021** attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "*Review of Interim Financial Information performed by Independent auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR PRATEEK JAIN AND CO.
CHARTERED ACCOUNTANTS
FRN-009494C**



Prateek Jain

**PRATEEK JAIN
PROPRIETOR
M. No. 079214**

**Date: 11th August, 2021
Place: Indore**

UDIN: 21079214AAAABS8040